Alnylam
Alnylam is a biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases.
Business Model:
Revenue: $960.9M
Employees: 1,001-5,000
Industries / Tags:
Detailed Alnylam Information
Geographic Data
Address: 675 West Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
post ipo debt
Raised Last:
$750M
Raised Total:$3B
Social
Metrics
823,907Website Global Rank
45,256Website Monthly Traffic
Twitter Followers
Description
Alnylam is a biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases.
Contact Phone:
+16175518200
Contact Email:
Alnylam went public on 6/4/2004 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/4/2004
IPO Valuation:
$114M
Ticker Symbol:
ALNY
IPO Price:
$6/share
Amount Raised:
$30M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2019 | Post-IPO Equity | $0 |
Regeneron Regeneron Regeneron Regeneron |
1/2014 | Post-IPO Equity | $0 |
Genzyme Genzyme Genzyme Genzyme |
4/2020 | Post-IPO Equity | 1 | $250M |
Blackstone Life Sciences Blackstone Life Sciences Blackstone Life Sciences Blackstone Life Sciences |
3/2011 | Post-IPO Equity | 1 | $10M |
Takeda Takeda Takeda Takeda |
1/2019 | Post-IPO Equity | $387.5M | 9/2022 | Post-IPO Debt | $1B | 5/2017 | Post-IPO Equity | $359.4M | 4/2020 | Post-IPO Debt | $2B |
Blackstone |
1/2015 | Post-IPO Equity | $450M | 1/2015 | Post-IPO Equity | $450M | 9/2022 | Post-IPO Debt | $900M | 4/2020 | Post-IPO Debt | 1 | $750M |
Blackstone Credit Blackstone Credit Blackstone Credit Blackstone Credit |
7/2003 | Private Equity Round | 6 | $24.6M |
Atlas Venture ARCH Venture Partners Abingworth Cardinal Partners Polaris Partners Merck Atlas Venture ARCH Venture Partners Abingworth Cardinal Partners Polaris Partners |
4/2019 | Post-IPO Equity | 1 | $800M |
Regeneron Regeneron Regeneron Regeneron |
1/2014 | Post-IPO Equity | 1 | $700M |
Genzyme Genzyme Genzyme Genzyme |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 9/2003 | Ribopharma AG |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
